Triple

Target class: Parkinson’s disease medication
Context triple: [entacapone, instanceOf, Parkinson’s disease medication]

• A. Alzheimer’s disease drug
  An Alzheimer’s disease drug is a pharmacological agent designed to prevent, slow, or alleviate the cognitive and functional decline associated with Alzheimer’s pathology, typically by targeting amyloid, tau, neurotransmitter systems, or related neurodegenerative mechanisms.
• B. aromatic L-amino acid decarboxylase inhibitor
  An aromatic L-amino acid decarboxylase inhibitor is a drug that blocks the enzyme responsible for converting aromatic L-amino acids (like levodopa) into their corresponding neurotransmitters, thereby increasing the availability of these precursors for therapeutic use, particularly in Parkinson’s disease.
• C. medication chosen
  A medication is a substance or combination of substances administered to diagnose, treat, prevent, or alleviate symptoms of disease or medical conditions in humans or animals.
• D. multiple sclerosis medication
  A multiple sclerosis medication is a drug or therapeutic agent designed to modify the disease course, manage relapses, or alleviate symptoms in individuals with multiple sclerosis by targeting immune or neurological processes.
• E. dopamine receptor antagonist
  A dopamine receptor antagonist is a drug that binds to dopamine receptors without activating them, thereby blocking dopamine’s effects and modulating neural signaling in conditions such as psychosis, nausea, and movement disorders.
• F. None of above.